false
0001894525
0001894525
2026-11-12
2026-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 12, 2026
Apimeds Pharmaceuticals US, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-42545 |
|
85-1099700 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification Number) |
|
100 Matawan Rd, Suite 325
Matawan, New Jersey |
|
07747 |
| (Address of principal executive offices) |
|
(Zip code) |
Registrant’s telephone number, including
area code: (848) 201-5010
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.01 per share |
|
APUS |
|
NYSE American LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01. Entry into a Material Definitive
Agreement.
Amendment
As
previously announced, on August 19, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “Company”),
entered into an Assignment and Transfer Agreement of Certain Apitox Rights (the “Assignment Agreement”) with FreeT
Inc., a company organized under the laws of the Republic of Korea (“FreeT”). FreeT is the successor to CNP Roen Co.,
Ltd., which subsequently changed its corporate name to Inscobee Co., Ltd. and is currently known as FreeT Inc.
Pursuant
to the Assignment Agreement, FreeT irrevocably assigned, transferred, conveyed and delivered to the Company all of FreeT’s right,
title and interest in and to certain Apitox-related rights (the “Assigned Rights”) that were originally acquired by
CNP Roen Co., Ltd. under an Apitox Rights Transfer Agreement dated June 16, 2015 (the “2015 Agreement”). On November
12, 2026, the Company and FreeT entered into that certain Amendment No. 1 to the Assignment and Transfer Agreement of Certain Apitox Rights
(the “Amendment”) to clarify the consideration paid to FreeT in connection with the Assigned Rights under Article 7
of the Assignment Agreement. The Assignment Agreement and the Amendment is governed by the laws of the Republic of Korea, with exclusive
jurisdiction in the Seoul Central District Court.
Valuation
and Consideration
Pursuant
to the Amendment, the Company shall issue to FreeT 350,000 shares of common stock of the Company no later than December 1, 2026 (the “Initial
Payment”). Within sixty days of the date of the Amendment, the Company and FreeT shall jointly appoint an independent third-party
valuer of recognized standing with experience in the valuation of pharmaceutical and life-sciences rights to determine the fair value
of the Assigned Rights (the “Valuation”). If the Valuation exceeds the Initial Payment, the Company shall pay
the additional amount to FreeT within thirty days of the completion of the Valuation, in cash, common stock, or a combination of cash
and common stock at the discretion of the Company.
The
foregoing summary of the Amendment does not purport to be a complete description and is qualified in its entirety by reference to the
full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference.
Item 3.02 Unregistered
Sales of Equity Securities.
The
disclosure set forth above in Item 1.01 of this Current Report on Form 8-K in the sections titled “Valuation and Consideration”
is incorporated into this Item 3.02 by reference. The issuance of the Initial Payment have not been registered under the Securities Act
of 1933, as amended (the “Securities Act”), in reliance upon the exemption from registration provided by Section 4(a)(2)
of the Securities Act.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. |
|
Description |
| 10.1 |
|
Amendment No. 1 to Assignment and Transfer Agreement of Certain Apitox Rights, dated November 12, 2026, by and between Apimeds Pharmaceuticals US, Inc. and FreeT Inc. |
| 104 |
|
Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Apimeds Pharmaceuticals US, Inc. |
| |
|
| Date: November 20, 2026 |
By: |
/s/ Dr. Vin Menon |
| |
Name: |
Dr. Vin Menon |
| |
Title: |
Co-Chief Executive Officer |
| |
By: |
/s/
SungJoon Chae |
| |
Name: |
SungJoon Chae |
| |
Title: |
Co-Chief Executive Officer |